Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TMDX 
TransMedics Group Inc (TMDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/03/2025: TMDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $135.86
1 Year Target Price $135.86
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.25% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.53B USD | Price to earnings Ratio 92.42 | 1Y Target Price 135.86 |
Price to earnings Ratio 92.42 | 1Y Target Price 135.86 | ||
Volume (30-day avg) 9 | Beta 2.08 | 52 Weeks Range 55.00 - 177.37 | Updated Date 07/1/2025 |
52 Weeks Range 55.00 - 177.37 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.03% | Operating Margin (TTM) 19.12% |
Management Effectiveness
Return on Assets (TTM) 4.21% | Return on Equity (TTM) 22.99% |
Valuation
Trailing PE 92.42 | Forward PE 72.46 | Enterprise Value 4743855450 | Price to Sales(TTM) 9.29 |
Enterprise Value 4743855450 | Price to Sales(TTM) 9.29 | ||
Enterprise Value to Revenue 9.72 | Enterprise Value to EBITDA 55.21 | Shares Outstanding 33833800 | Shares Floating 32830616 |
Shares Outstanding 33833800 | Shares Floating 32830616 | ||
Percent Insiders 3.03 | Percent Institutions 121.56 |
Analyst Ratings
Rating 3 | Target Price 135.86 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TransMedics Group Inc
Company Overview
History and Background
TransMedics Group Inc. was founded in 1998. The company pioneered the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to improve organ preservation and viability for transplantation. They went public in 2019.
Core Business Areas
- Organ Care System (OCS): The OCS is a portable system that keeps organs viable and functioning outside the human body during transport for transplantation. It perfuses the organ with warm, oxygenated, nutrient-rich blood or solution, maintaining it in a near-physiological state. It includes solutions, disposables and services.
Leadership and Structure
Waleed Hassanein, MD, is the President and Chief Executive Officer. The company has a typical corporate structure with a Board of Directors overseeing management.
Top Products and Market Share
Key Offerings
- Organ Care System (OCS) Heart: The OCS Heart system is used to preserve and assess hearts for transplantation. TransMedics is the leader in ex-vivo heart preservation. Competitors include Paragonix Technologies.
- Organ Care System (OCS) Lung: The OCS Lung system is used to preserve and assess lungs for transplantation. TransMedics is the leader in ex-vivo lung preservation. Competitors include Paragonix Technologies.
- Organ Care System (OCS) Liver: The OCS Liver system is used to preserve and assess livers for transplantation. TransMedics is the leader in ex-vivo liver preservation. Competitors include Paragonix Technologies.
Market Dynamics
Industry Overview
The organ transplantation market is driven by the increasing prevalence of organ failure and the growing demand for transplantable organs. There is a significant shortage of organs available for transplant, creating a need for better preservation and assessment technologies.
Positioning
TransMedics is a leader in the ex-vivo organ preservation market with its OCS technology. Its competitive advantage lies in its proprietary technology that improves organ viability and allows for the transplantation of organs that might otherwise be deemed unsuitable.
Total Addressable Market (TAM)
The TAM for organ preservation is estimated to be billions of dollars. TransMedics, with its OCS technology, is positioned to capture a significant portion of this market, especially as adoption rates for ex-vivo preservation increase.
Upturn SWOT Analysis
Strengths
- Proprietary OCS technology
- Established market leadership in ex-vivo organ preservation
- Strong clinical data supporting the effectiveness of OCS
- Growing adoption by transplant centers
Weaknesses
- High cost of OCS systems and disposables
- Reliance on a single product platform
- Relatively small company size compared to potential competitors
- Requires specialized training for use
Opportunities
- Expansion into new organ types (e.g., kidney)
- Increased adoption of OCS by transplant centers globally
- Development of new OCS features and capabilities
- Partnerships with organ procurement organizations (OPOs)
Threats
- Competition from established medical device companies
- Regulatory hurdles for new products and applications
- Reimbursement challenges for OCS procedures
- Technological advancements from competitors
Competitors and Market Share
Key Competitors
- Paragonix Technologies
- Organ Recovery Systems
Competitive Landscape
TransMedics has a first-mover advantage and a strong clinical data track record. However, competitors are developing their own organ preservation technologies, creating a competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: TransMedics has experienced significant revenue growth in recent years due to increasing adoption of the OCS technology.
Future Projections: Analysts project continued revenue growth for TransMedics, driven by increased adoption of OCS and expansion into new markets. Profitability is expected to improve as the company achieves greater scale.
Recent Initiatives: Recent initiatives include expanding commercial operations, developing new OCS applications, and strengthening relationships with transplant centers and OPOs.
Summary
TransMedics is a leading company in the ex-vivo organ preservation market, boasting a proprietary OCS technology and strong clinical data. The company is experiencing robust revenue growth and faces challenges in competition, scalability, and reimbursement. Continued investment in innovation and strategic partnerships are vital. TransMedics is well positioned for future growth in the organ transplant market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TransMedics Group Inc
Exchange NASDAQ | Headquaters Andover, MA, United States | ||
IPO Launch date 2019-05-02 | Founder, President, CEO & Director Dr. Waleed H. Hassanein M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 728 | Website https://www.transmedics.com |
Full time employees 728 | Website https://www.transmedics.com | ||
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.